5-Amino-1MQ gets described as a fat-loss compound constantly, but the actual mechanism runs through an enzyme most people have never heard of: NNMT. Understand that enzyme and the NAD+ connection, and the rest of the compound’s research profile makes a lot more sense than the shorthand “fat-loss peptide” label usually communicates on its own.

The enzyme at the center of it

NNMT, short for nicotinamide N-methyltransferase, is an enzyme that regulates how your cells handle nicotinamide, a precursor to NAD+. NNMT methylates nicotinamide into a different molecule, 1-methylnicotinamide, which pulls it out of the pathway your cells would otherwise use to build NAD+. 5-Amino-1MQ is studied as a competitive inhibitor of this exact enzyme.

Why blocking NNMT matters for NAD+

Block NNMT, and nicotinamide flows back into NAD+ production instead of getting diverted. That’s the entire basis for calling this compound “NAD+-adjacent” rather than a direct NAD+ compound. It doesn’t supply NAD+ the way a NAD+ product does. It’s studied for raising NAD+ indirectly, by removing the enzyme that was draining the precursor supply.

Where fat cell research comes in

Higher intracellular NAD+ activates SIRT1 and SIRT3, enzymes that depend on NAD+ to function and that play a role in mitochondrial activity and fat oxidation. Separately, elevated levels of another byproduct of NNMT inhibition (SAM) shift the balance in stem cells away from becoming fat cells and toward becoming muscle or bone cells instead. In animal studies, this combination has been associated with increased UCP1 expression, a marker of “browning,” where energy-storing white fat shifts toward a more metabolically active, heat-generating profile.

Why NNMT specifically draws so much research attention

NNMT isn’t a niche target picked at random. It sits at a genuine crossroads between methylation biology and NAD+ metabolism, two systems that both decline with age and both get studied heavily in longevity research generally. An enzyme that touches both pathways at once, the way NNMT does, is the kind of target researchers get excited about specifically because inhibiting it could theoretically influence more than one aging-related process through a single mechanism, rather than needing separate interventions for each system.

That’s also exactly why it’s worth being careful about how far to extrapolate from the mechanism alone. A compound touching two important pathways at once is scientifically interesting. It isn’t the same as evidence that touching both pathways produces a specific, measurable outcome in a living person.

What the research actually covers right now

This is the part worth being direct about: every finding above comes from preclinical research in rodent models. Studies have shown reductions in fat mass and improved metabolic markers without changes to food intake, which is a genuinely interesting result. It’s also not the same as a published human clinical trial, and no such trial exists for this compound as of this writing. The mechanism is well-mapped at the cellular level. The jump to confirmed human outcomes hasn’t happened yet.

Rodent studies are a legitimate first step in almost every compound’s research history, and there’s nothing unusual about 5-Amino-1MQ sitting at this stage. What’s worth avoiding is treating “the enzyme mechanism is well-understood” and “the compound produces this effect in a person” as the same claim. They’re related, but one is settled cellular biology and the other is an open question that a rodent study, however well designed, doesn’t answer on its own.

How this fits alongside other fat-loss research

5-Amino-1MQ’s NAD+-adjacent mechanism is a genuinely different approach from most of what shows up in fat loss research. Compounds like AOD-9604 and Tesamorelin work through the growth hormone axis, while CJC-1295 and GHRP-2 target GH release through their own pathways entirely. 5-Amino-1MQ’s enzyme-inhibition route sits apart from all of those. If longevity research is part of what interests you here, our MOTS-c spotlight covers a compound studied through a related metabolic-health angle, worth reading for the contrast in mechanism.

Other fat-loss-adjacent compounds worth knowing about while you’re comparing options include HGH Fragment 176-191, Sermorelin, and L-Carnitine, each studied through its own distinct mechanism rather than interchangeably. Treating an entire shelf of fat-loss-adjacent compounds as one interchangeable category is a common shortcut, and it’s the wrong one. The mechanism behind each compound is what actually determines whether it’s relevant to the specific question you’re researching.

Handling and sourcing

Reconstitution and storage matter regardless of which compound you’re researching. Our Peptide Prep 101 guide and peptide mixing calculator cover getting the reconstitution math right, and our piece on storing peptides as temperatures rise covers keeping a compound stable once it’s mixed.

Check our FAQs for common ordering questions, browse the full shop for everything we carry, and our blog has more research breakdowns like this one. Existing customers can track an order or check a rewards balance from their account, and our About Us page covers who we are.

Nothing here is medical advice. Talk to a qualified healthcare professional before starting any new compound, and check what’s legal where you live.